Cite
HARVARD Citation
Larocca, A. et al. (2022). Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. British journal of haematology. pp. 639-648. [Online].